The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study

Diabetes is a common cause of chronic kidney disease (CKD), but in aggregate, non-diabetic diseases account for a higher proportion of cases of CKD than diabetes in many parts of the world. Inhibition of the renin–angiotensin system reduces the risk of kidney disease progression and treatments that...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Clin Kidney J
Päätekijät: Herrington, William G, Preiss, David, Haynes, Richard, von Eynatten, Maximilian, Staplin, Natalie, Hauske, Sibylle J, George, Jyothis T, Green, Jennifer B, Landray, Martin J, Baigent, Colin, Wanner, Christoph
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Oxford University Press 2018
Aiheet:
Sglt-2 Inhibition
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6275453/
https://ncbi.nlm.nih.gov/pubmed/30524708
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ckj/sfy090
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia